SCHEMBL506960

SCHEMBL506960

N#Cc1ccc2ccoc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.71
MAOA P21397 2/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
NFKB1 P19838 1/20 0.40
ACHE P22303 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
PGR P06401 2/20 0.38
HTR1B P28222 5/20 0.38
CYP17A1 P05093 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
IMPDH2 P12268 1/20 0.37
IMPDH1 P20839 1/20 0.37
NOS3 P29474 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29968261 0.83 CYP2A6 (1.00) CYP2A6MAOACA1CA2PGR
SCHEMBL827799 0.83 CYP2A6 (1.00) CYP2A6MAOACA1CA2PGR
SCHEMBL96525 0.79 CYP2A6 (0.46) CYP2A6MAOAKDM4ECYP3A4CYP2D6
SCHEMBL5780690 0.73 GRM5 (0.64) CYP2A6MAOAKDM4ECA1CA2
SCHEMBL30744099 0.73 GRM5 (0.64) CYP2A6MAOAKDM4ECA1CA2
SCHEMBL9431131 0.72 PGR (0.63) CYP2A6MAOAKDM4ECYP3A4CYP2D6
Phenylacetylene SCHEMBL28207262 0.72 GRM5 (0.43) CYP2A6MAOAKDM4ECYP3A4CYP2D6
SCHEMBL29489119 0.71 CYP2A6 (0.54) CYP2A6CA1CA2CYP17A1CYP11B1
SCHEMBL1344485 0.71 CYP2A6 (0.54) CYP2A6CA1CA2CYP17A1CYP11B1
SCHEMBL11187458 0.71 HTR1B (0.49) CYP2A6MAOAKDM4ECYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4293029-B1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) 2025-12-17 EP disclosed
WO-2024259241-A1 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF Transneural Therapeutics, Inc. (US) 2024-12-19 WO disclosed
CN-112409385-B Azaaryl compounds and uses thereof 上海青煜医药科技有限公司 2024-08-13 CN disclosed
US-20240182492-A1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) 2024-06-06 US disclosed
EP-4293029-A1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Blueray Biopharma Co., Ltd. (CN) 2023-12-20 EP disclosed
US-20230355705-A1 DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS THE UNIVERSITY OF HONG KONG (CN) 2023-11-09 US disclosed
WO-2022171166-A1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海青煜医药科技有限公司 2022-08-18 WO disclosed
CN-114907385-A Nitrogen heteroaryl compound, preparation method and application thereof 上海青煜医药科技有限公司 2022-08-16 CN disclosed
US-11246862-B2 Process for the preparation of lifitegrast MANKIND PHARMA LTD. (IN) 2022-02-15 US disclosed
US-20200306242-A1 NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST MANKIND PHARMA LTD. (IN) 2020-10-01 US disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-7645400-B2 Composition containing carbon nanotubes having a coating MITSUBISHI RAYON CO., LTD. (JP) 2010-01-12 US disclosed
US-20090321688-A1 Carbon Nanotube Composition, Composite Having a Coated Film Composed of the Same, and Their Production Methods MITSUBISHI RAYON CO., LTD. (JP) 2009-12-31 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed
EP-1720836-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2006-11-15 EP disclosed
US-20060052509-A1 Composition containing carbon nanotubes having coating thereof and process for producing them MITSUBISHI RAYON CO., LTD. (JP) 2006-03-09 US disclosed
WO-2005082859-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 CYP2A6 799/4885MAOA 462/4885KDM4E 1208/4885
US-11246862-B2 Process for the preparation of lifitegrast LIFR, PTGFR, CSF1R CYP2A6 782/4885MAOA 988/4885KDM4E 3081/4885
US-20240182492-A1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF EZH2, EED, EZH1 CYP2A6 1327/4885MAOA 4009/4885KDM4E 108/4885
US-20230355705-A1 DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS YEATS2, YEATS4, KNTC1 CYP2A6 4559/4885MAOA 3382/4885KDM4E 351/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A CYP2A6 438/4885MAOA 170/4885KDM4E 623/4885
US-20200306242-A1 NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST LIFR, CSF1R, CSF3R CYP2A6 920/4885MAOA 994/4885KDM4E 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.